+

WO1999002704A3 - Dual specifically phosphatase and methods of use - Google Patents

Dual specifically phosphatase and methods of use Download PDF

Info

Publication number
WO1999002704A3
WO1999002704A3 PCT/US1998/014205 US9814205W WO9902704A3 WO 1999002704 A3 WO1999002704 A3 WO 1999002704A3 US 9814205 W US9814205 W US 9814205W WO 9902704 A3 WO9902704 A3 WO 9902704A3
Authority
WO
WIPO (PCT)
Prior art keywords
pten
methods
phosphatase
dual
specifically
Prior art date
Application number
PCT/US1998/014205
Other languages
French (fr)
Other versions
WO1999002704A2 (en
Inventor
Nicholas K Tonks
Michael P Myers
Original Assignee
Cold Spring Harbor Lab
Nicholas K Tonks
Michael P Myers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab, Nicholas K Tonks, Michael P Myers filed Critical Cold Spring Harbor Lab
Priority to AU84794/98A priority Critical patent/AU8479498A/en
Publication of WO1999002704A2 publication Critical patent/WO1999002704A2/en
Publication of WO1999002704A3 publication Critical patent/WO1999002704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PTEN proteins and altered PTEN proteins, and the nucleic acid molecules encoding them are described. Also described are methods of diagnosis and treatment, e.g., of prostate cancer, utilizing compositions comprising PTEN or altered PTEN or nucleic acid molecules encoding PTEN or altered PTEN.
PCT/US1998/014205 1997-07-08 1998-07-08 Dual specifically phosphatase and methods of use WO1999002704A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU84794/98A AU8479498A (en) 1997-07-08 1998-07-08 Dual specificity phosphatase and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5190897P 1997-07-08 1997-07-08
US60/051,908 1997-07-08
US9098498P 1998-06-29 1998-06-29
US60/090,984 1998-06-29

Publications (2)

Publication Number Publication Date
WO1999002704A2 WO1999002704A2 (en) 1999-01-21
WO1999002704A3 true WO1999002704A3 (en) 1999-04-01

Family

ID=26729940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014205 WO1999002704A2 (en) 1997-07-08 1998-07-08 Dual specifically phosphatase and methods of use

Country Status (2)

Country Link
AU (1) AU8479498A (en)
WO (1) WO1999002704A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
WO2000060092A2 (en) * 1999-04-07 2000-10-12 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US7078210B2 (en) 1999-07-02 2006-07-18 Ceptyr, Inc. DSP-3 dual-specificity phosphatase
WO2001002581A1 (en) * 1999-07-02 2001-01-11 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US6284538B1 (en) 1999-07-21 2001-09-04 Isis Pharmaceuticals, Inc. Antisense inhibition of PTEN expression
AU6903800A (en) * 1999-08-13 2001-03-13 Sugen, Inc. Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders
AU2001247782A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
AU6513701A (en) * 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
KR20040018598A (en) * 2002-08-23 2004-03-04 코웰창업투자(주) Tat-pten fusion protein and process for its preparation and its use
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004074459A2 (en) * 2003-02-19 2004-09-02 Georgetown University Pten-deficient cells and their uses
CN104740614A (en) 2009-10-16 2015-07-01 不列颠哥伦比亚大学 Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015686A1 (en) * 1995-10-23 1997-05-01 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
WO1998033907A1 (en) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015686A1 (en) * 1995-10-23 1997-05-01 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
WO1998033907A1 (en) * 1997-01-30 1998-08-06 Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL - EMHUM2 3 April 1997 (1997-04-03), LI, J. ET AL.: "Human putative protein tyrosine phosphatase (PTEN) mRNA, complete cds.", XP002066159 *
DATABASE EMBL - EMHUM2 3 April 1997 (1997-04-03), STECK, P.A. ET AL.: "Human mutated in multiple advanced cancers protein (MMAC1) mRNA, complete cds.", XP002066161 *
LI, D-M. ET AL.: "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.", CANCER RESEARCH, vol. 57, 1 June 1997 (1997-06-01), pages 2124 - 2129, XP002066157 *
LI, J. ET AL.: "PTEN, a putative tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.", SCIENCE, vol. 275, 28 March 1997 (1997-03-28), pages 1943 - 1946, XP002066155 *
MAEHAMA, T. ET AL.: "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 22, 29 May 1998 (1998-05-29), pages 13375 - 8, XP002088259 *
MYERS, M. ET AL.: "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatse.", PROC.NATL.ACAD.SCI.USA, vol. 94, August 1997 (1997-08-01), XP002088258 *
PAYRASTRE, B. ET AL.: "Phosphoinositide 3-phosphatase segregates from phosphatidylinositol 3-kinase in EGF-stimulated A431 cells and fails to in vitro hydrolyse phosphatidylinositol(3,4,5)trisphosphate.", FEBS LETTERS, vol. 341, 1994, pages 113 - 8, XP002088256 *
STECK, P.A. ET AL.: "Identification of a candidate tumor suppressor gene at 10q23.3 that is mutated in multiple advanced cancers, MMAC1.", NATURE GENETICS, vol. 15, April 1997 (1997-04-01), pages 356 - 363, XP002066156 *
ZHOU, G. ET AL.: "The catalytic role of Cys124 in the dual specificity phosphatase VHR.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 28084 - 90, XP002088257 *

Also Published As

Publication number Publication date
AU8479498A (en) 1999-02-08
WO1999002704A2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2000028090A3 (en) Diagnostic assay for cancer
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2000018914A3 (en) Novel dkr polypeptides
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2000066528A3 (en) Quinones for treatment of diseases
WO2000053776A3 (en) Human kallikrein-like genes
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
DK1082423T3 (en) Cyclin E2 genes and proteins
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
WO2001042474A3 (en) Interferon-like molecules and uses thereof
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
MX9806041A (en) PURIFIED SR-p70 PROTEIN.
AU7147898A (en) (dirofilaria) and (brugia) ankyrin proteins, nucleic acid molecules, and uses thereof
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
WO2001059120A3 (en) Il-17 like molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载